reason report
bottom line today publish first seri piec
ttr amyloidosi market initi focu impact
renegoti agreement sni op market
opportun present addit ttr indic full control
ttr franchis increas bullish abil
expand size pie patisiran ttrsc sq especi
wild-typ ttr diseas howev enthusiasm soften one
confound factor second gen medicin look much
attract even price pariti much less profit product
even expand ttr market opportun cannib
patisiran view inevit within consid revenu
potenti addit ttr indic market expans via
sq balanc clinical/commerci risk variou patisiran
cannib scenario remain mp increas pt
first multipl note ttr seri explor
multipl key commerci question know wild-typ
ttr amyloidosi much addit indic wild-
type ttr expand revenu opportun convers
launch ttrsc greater royalti burden mean
ttr franchis overal net revenu potenti variou level market
penetr variou magnitud patisiran cannib
ttrsc success would undeni repres posit
howev econom recent sni deal render key variabl
rel price patisiran vs ttrsc pace share loss
patisiran revenu potenti addit indic
greater interest relev valuat
potenti indic outlin sq wild-typ
ttr view interest area market expans
broaden pursuit beyond hereditari
attr patient popul patisiran apollo studi
compani recent announc plan pursu multipl new
indic includ wild-typ attr asymptomat diseas wild-
type could signific popul estim
much bigger hereditari attr though diagnosi rate
major unknown point sensit model hereditari
form diseas wild type attr thought caus
deposit ttr aggreg throughout bodi therebi offer
strong mechanist rational approach
new price target base multipl
scenario blend two differ commerci path
dcf analysi discount rate
per share net
includ recent equiti rais recent privat
placement option
compani inform leerink partner llc research
revenu million ep
pleas refer page import disclosur price chart analyst certif
ad new indic increas odds-of-success
ttrsc also aggress assum sq may
ultim replac vast major patisiran usag hereditari attr
hattr patient new patient wild-typ greater overal share
hattr total revenu perspect make
rel poorer econom associ sq plan phase
studi succeed howev new model pace chang
net ttr revenu lag growth rate ttr patient
therapi hypothet scenario
patisiran patient switch sq latter peak royalti rate
pariti price need expand treat ttr popul
keep total net revenu consid
valu dcf via blend two scenario one
assum gener drug reach market like view
anoth ttrsc fail patisiran protect move
ttr-opathi
rate share market perform develop lead therapeut rnai
platform industri enabl specif inhibit liver express gene target high
level effici although rnai therapeut categori still repres less valid
treatment modal rel drug class monoclon antibodi small molecul drug
believ platform ip posit pipelin repres tremend sourc upsid
view augment develop regulatori risk also draw confid
outstand clinic data gener alni lead clinic program patisiran hereditari ttr
amyloidosi remain optimist data differenti
mp inotersen expect reach market convers key
asset fitusiran hemophilia somewhat riskier view especi given recent
safeti issu compet much crowd therapeut area
efficacy/safeti hurdl higher givosiran porphyria remain one excit
pipelin program howev believ current valuat alreadi ascrib consider
amount valu late stage asset technolog platform broadli
ttr-sq fulli alni control addit
indic horizon
sq fulli control plan studi drug addit ttr indic
could expand revenu opportun ttr categori virtu renegoti term
agreement sni fulli driver seat ttr amyloidosi attr
franchis theyv also made clear intent expand market opportun ttr
knockdown drug target wild type non-hereditari attr asymptomat hereditari
attr current cover first gener drug biggest potenti
opportun view elect pursu wild type attr patient preval
estim much bigger hereditari attr wed expect success also
separ recent announc sq program hattr would lead meaning cannib
patisiran discuss follow howev wild type market look big enough view
compens poorer econom alni second gener ttr knockdown drug
overal incorpor wild type patient bigger hereditari attr opportun
model estim could doubl number attr patient receiv
rnai drug potenti add net us eu revenu time
outcom howev risk-adjust model variou scenario sq price
pace patisiran cannib influenc magnitud market expans
preval wild type attr easi diagnos epidemiolog appear
less well-understood hereditari attr wild type attr wt-attr also refer
non-hereditari attr senil cardiac amyloidosi senil system amyloidosi believ
caus deposit ttr protein aggreg similar occur hereditari attr
likewis ttr deposit wild type patient lead multisystem disord though also
similarli cardiomyopathi predomin phenotyp major case addit wt-
attr diseas onset tend occur late life literatur estim number wt-attr
patient rang wide approx world-wide mani popul
year age estim autopsi one challeng pinpoint number
patient present clinic symptom wt-attr symptom overlap
cardiac diseas exampl posit indic wt-attr older patient
thicken ventricular wall identifi echocardiogram could also attribut hypertroph
cardiomyopathi even hypertens diagnosi wild type patient follow similar pathway
abnorm find electrocardiographi lead echocardiograph test
measur nt-probnp troponin two protein inform cardiac diseas may also
inform diagnosi definit diagnosi come endomyocardi biopsi
commonli requir distinguish ttr light chain amyloidosi type given
cumbersom natur diagnost process mani case wt-attr thought remain
either undiagnos diagnos late advanc highli symptomat stage
diseas cours wt-attr similar though averag less aggress
hereditari cardiomyopathi attr recent commiss medacorp survey attr
physician link see hereditari wild type attr patient
ask sever wt-attr compar hereditari attr follow data
initi publish survey note reserv respons futur plan research
wild-typ diseas averag respond indic roughli half
diagnos wild-typ patient least sever hattr popul indic us
wild type diseas view slightli less aggress line base
review literatur median surviv wt-attr year slightli less
what seen hereditari cardiomyopathi attr year also consist
small observ studi wt-attr patient hereditari attr steadi
declin worsen observ averag distanc patient abl walk
minut walk test though wild type patient progress slower pace hereditari patient
cardiomyopathi
survey question percent wild type ttr amyloidosi patient would character
symptom least sever hereditari ttr amyloidosi
physician see hereditari wild type attr patient
today wt-attr patient treat similar manner hereditari cardiomyopathi attr
patient avail treatment larg ineffect modifi heart-failur treatment
use support treatment toxic possibl worsen symptom
concern pacemak implant cardiovert defibril also mention treatment
guidelin though point devic may prevent sudden cardiac death
ttr deposit may actual caus electromechan defect ttr stabil tafamidi
approv eu earli stage hereditari polyneuropathi patient diflunis gener
approv attr design target underli caus diseas
shown modest impact polyneuropathi symptom hattr also
may less relev wild-typ popul howev mp current conduct
studi high dose tafamidi hereditari attr patient cardiomyopathi wild type
think data could impact use stabil wild type patient given similar
natur clinic present cardiomyopathi diseas mechan ttr protein
aggreg studi expect complet final organ
transplant option though often contraind due advanc age mani wt-
gener data hereditari attr patient mild
cardiomyopathi symptom view support ttr knockdown approach
wild type patient howev efficaci sever cardiac patient given
phase patisiran inotersen studi conduct determin
approxim half studi popul level mild cardiac involv consist
new york heart associ class subgroup analys conduct compani
suggest ttr knockdown approach abl posit impact cardiac aspect
diseas although studi focus hereditari patient mechanist
read posit onto wild-typ though trial design perspect natur histori
diseas progress latter could quit differ
recent medacorp survey also affirm enthusiasm ttr knockdown
approach wild type patient high although wt-attr distinct hereditari attr
number way diseas onset later nearli patient cardiomyopathi phenotyp
genet mutat caus ttr aggreg physician queri
indic expect oligonucleotide-bas therapi effect form
diseas mechanist wt-attr believ caus ttr aggreg ttr
knockdown approach solid chanc efficaci diseas set manner
similar what shown hereditari patient model today howev includ
risk uncertainti surround trial design/pati select need larger
safeti databas sq
survey question base phase data expect oligonucleotide-bas therapi
effect wild type ttr amyloidosi
model assum preval wild type patient bigger
preval hereditari patient patient ww though cut treatabl patient pool
significantli assum diagnosi rate literatur estim vari consider
difficulti diagnosi take conserv view ww
preval wt-attr closer patient regard diagnosi rate studi
data collect uk nation amyloidosi centr found autopsy-confirm wt-
attr case mention amyloid death certif studi pinney et al
interest inform rate diagnosi patient end see amyloid
specialist howev may less relev diagnosi rate broader popul howev
studi recent japanes survey wt-attr patient impli much lower
diagnosi rate wild-typ diseas describ medacorp specialist survey
refer gener less seriou hattr medacorp specialist estim
hattr diagnosi rate make sens diagnosi rate wild-typ
also lack clear genet compon may lower consid estim diagnosi
rate number truli estim worth note chang wild
type diagnosi rate model chang price target consist
model diagnosi rate hereditari attr forecast diagnosi rate wt-attr
increas advent diseas modifi therapi due increas awar
higher motiv treat
balanc physician feedback uniqu characterist wt-attr
lack clinic data date impli product profil unknown lead us forecast
peak penetr wild type patient ttrsc ttr aggreg thought
underli caus form attr includ wild type believ ttr knockdown
reason shot broadli effect howev model opportun compar
hattr peak penetr higher take item consider first
consid wild type attr appear less progress cardiomyopathi form hattr
secondli averag age diseas onset wild type patient older may therefor lead
differ risk/benefit conclus younger equal sever hereditari ttr patient
third take account wild-typ ttr diagnosi isnt straightforward given overlap
clinic symptom diseas even advent effect therapi identifi
wild type patient like remain challeng final also consid
option patient render bar ttrsc drug develop
opportun asymptomat ttr patient carri disease-caus mutat
repres upsid estim variou reason includ sale
patient subset model today indic also seek expand
ttr market opportun sq via pursuit current asymptomat patient ttr
amyloidosi disease-caus mutat although theoret could expand pool
patient take knockdown medicin practic think challeng pursuit
absenc symptom patient could extrem difficult identifi
anticip current identif rate may low run trial design
popul may also difficult face uncertainti regard necessari durat
treatment like long show placebo separ best measur benefit
clinic trial final also see payor risk asymptomat ttr
reimburs argument expect drug may rel
challeng complianc may also hard model
although renegoti agreement sni give full control ttr franchis
ttrsc success think cannib patisiran somewhat inevit mean
patient need sq arriv level net royalty-adjust revenu
although still earli develop believ subcutan administr profil
monthli quarterli dose schedul materi advanc patisiran given via
multi-hour infus pre-treat everi week furthermor level ttr
knockdown achiev healthi volunt appear modestli superior
patisiran may even lead differenti efficaci hattr elsewher
taken togeth anticip mani patient achiev diseas control first gener
ttr knockdown drug consid switch conveni possibl
efficaci even latter approv differ ttr-opathi indic
mean net revenu hattr specif assum ttrsc price
increment lower versu peak royalti burden everi patisiran
sq switch need find slightli addit patient either hattr
wild-typ initi sq order net revenu remain
net patisiran revenu risk adjust use probabl success
ttrsc price much lower patisiran theoret alni
incent complic pictur think evolv previous model
patisiran ttrsc complet separ conserv assumpt latter
also previous assum sq pure market expand new product
would take share patisiran hattr alni strategi ttrsc come focu
manner could vastli expand number patient treat simultan question
whether there viabl way protect patisiran franchis ttrsc-driven eros
nonetheless one area weve chang assumpt thought process
ttrsc potenti price vacuum wed gener assum much broader patient pool
target wild-typ along indic ttrsc rel patisiran
hattr would impli lower price former maxim access howev
weve thought decid previou price ttrsc
rel basi low price decis ttrsc fulli alni control dont think
itd make much sens make drug cheap given econom consider sni
royalti ttrsc refer far earli give real guidanc
matter think price sq thought strategi protect
patisiran franchis cannib major question investor mind
come year compani becom commerci organ
probabl success
probabl success
probabl success
probabl success
net patisiran revenu risk adjust use probabl success
explor commerci implic variou scenario associ ttr sq launch
rate pace cannib patisiran critic assumpt major
implic total revenu shown first chart follow one assum ttrsc
never use hattr use wild-typ ttr patient total net royalty-adjust
peak revenu hereditari attr estim greater even base
fewer patient convers one assum patisiran-tr patient end
switch sq new base case end treat greater number hattr patient
achiev less revenu specif ttr amyloidosi subset ultim expect wild-
type diseas success de-risk easili compens still expand market
lost hattr net-revenu howev follow dynam critic consid
valuat forecast potenti ttr-sq price
assum cannib differenti econom reduc net
base case expand market overal repres posit
valu driver model estim second gener drug increas
ttr categori expans wild type patient well hereditari attr
make lost revenu patisiran cannib hereditari attr base
assumpt conveni patisiran expect valu proposit
appeal greater number potenti less progress polyneuropathi patient
furthermor think could gain share within sever cardiac hattr market
gener clinic data categori someth that current lack patisiran
inotersen dataset could increas enthusiasm physician payer standpoint
model assum second gener drug increas peak penetr hereditari
polyneuropathi attr hereditari cardiomyopathi
attr howev weigh outstand success patisiran polyneuropathi patient
enigmat failur revusiran discontinu ttr knockdown drug candid sever
cardiomyopathi patient assum separ probabl success
popul model probabl success
polyneuropathi cardiomyopathi hattr respect consid wt-attr
predominantli manifest cardiac diseas consid uncertainti surround
program design target patient popul current odd success wild-typ
final given alni head start gener drug rel mp
current assum market share split favor lica
guarante gener drug reach market account dcf
incorpor two scenario follow-on product success develop lead least
cannib gener product likelihood follow-on product fail
reach market cannib occur likelihood incorpor two
scenario attempt captur inher risk develop rnai medicin
possibl endeavor may ultim fail first scenario assum
second gener ttr drug ultim reach market cannib patisiran
inotersen also expand peak ttr opportun via new indic greater
number patient therapi howev also includ second scenario instead follow-
product introduc marketplac patisiran inotersen remain
domin therapi mechan incorpor two scenario dcf
probability-weight basi probabl gener drug reach market
probabl wont togeth chang increas price target
toggl differ estim blend dcf model find price target
particularli sensit net price wt-attr penetr assumpt adjust
price estim swing price target likewis
adjust peak penetr steep adopt ramp wild type patient
move price target
sensit price differ estim net price
model steeper wt-attr adopt ramp higher peak penetr estim
banypersad sm et al updat cardiac amyloidosi review heart assoc
bhogal et al cardiac amyloidosi updat review emphasi diagnosi
gilmor jd et al analysi diseas progress patient transthyretin cardiac
amyloidosi orphanet journal diseas
grogan et al natur histori wild-typ transthyretin cardiac amyloidosi risk stratif
use novel stage system journal american cardiolog
pinney jh et al system amyloidosi england epidemiolog studi british journal
sekijima et al first nationwid survey system wild-typ attr amyloidosi japan
amyloid epub ahead print
price target month base probability-of-success adjust
dcf analysi appli discount rate termin growth rate similar
peer oligonucleotid compani coverag also transit commerci stage
compani model reflect genzym sni opted-in fitusiran instead
given larger potenti market opportun former within dcf use
blend two scenario ttrsc reach market expand ttr opportun
cannib patisiran ttrsc reach market seek expand
patisiran ttr indic
invest fundament high-risk high-reward invest view
competit manufactur risk import stock perspect clinic
develop risk associ patisiran possibl emerg innov competitor
possibl safeti issu around rnai technolog may emerg larg number
subject treat extend period time believ could
impact stock significantli
medacorp perform survey behalf leerink partner llc analyst analyst
conjunct medacorp develop question contain survey
number respond
unit state europ
respons repres averag unit state europ aggreg respons unless
screener best describ clinic specialti
screener best describ locat
screener mani patient hereditari ttr amyloidosi person treat see least per year
screener screener hereditari ttr amyloidosi patient person treat see least per year
mani would character follow
predominantli polyneuropathi
predominantli cardiomyopathi
mix phenotyp polyneuropathi cardiomyopathi
predominantli polyneuropathi
predominantli cardiomyopathi
mix phenotyp polyneuropathi cardiomyopathi
predominantli polyneuropathi
predominantli cardiomyopathi
mix phenotyp polyneuropathi cardiomyopathi
treat wild type ttr amyloidosi also refer non-hereditari senil ttr amyloidosi
mani patient wild type ttr amyloidosi person treat see least per year
percent wild type ttr amyloidosi patient would character symptom least
sever hereditari ttr amyloidosi
percent wild type ttr amyloidosi patient symptom
least sever hereditari ttr amyloidosi
base phase data expect oligonucleotide-bas therapi effect wild type ttr amyloidosi
appendix summari respons
appendix summari respons
question base phase data expect oligonucleotide-bas therapi effect wild type ttr
remain seen whether data translat benefit wild type patient
newer therapi avail soon continu refer amyloidosi patient larg referr center
hope receiv treatment
look forward approv rnai drug
mayb concern older age drug toxic less time benefit
knock technolog would effect wildtyp ttr amyloidosi
need data
mechan action similar although group uncommon enough may abl confirm
efficaci time
drug offer tx option may superior current avail altern sever diseas lead
reason see differ
reason oligonucleotid drug would work diseas state
end point appear amyloid infiltr probabl similar type
studi need done
robust data avail clinic use
tri new drug
lack altern treatment make worth tri
import tri new treatment
lack therapeut option patient poor prognosi high rate hospit heart failur
innov solut welcom base therapi promis
believ oligonucleotid base therapi would effect wild type ttr amyloidosi extent
person experi main factor use new product
 mm
mileston rev collabor
restructur tkmr licens agreement
total incom expens
bs cf mm
sec file leerink partner estim
chang
oper
invest
financ
sec file leerink partner estim
free equiti
row sni
mileston sny/genz p/w
sec file leerink partner estim
phase data icpp
half
